- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00360841
Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting
Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting: A Prospective Randomized Double-blind Cross-over Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chemotherapy-induced nausea and vomiting (CINV) are two of the most commonly reported adverse effects of chemotherapy. Uncontrolled CINV reduces quality of life, leads to delays in treatment, and causes serious metabolic disturbances. Current strategies for preventing acute CINV include combination therapy with a 5-HT3 antagonist and a corticosteroid for moderately-high to highly emetogenic chemotherapy. Similarly, strategies aimed at reducing the incidence and severity of delayed CINV include the combination of a corticosteroid and either a dopamine receptor antagonist or a 5-HT3 antagonist for 3-5 days post chemotherapy. Complete protection from vomiting in the first 24 hours is achieved in as many as 70-90% of patients receiving moderately-high and highly emetogenic chemotherapy; however, standard antiemetics only protect 50% of patients from experiencing nausea during this acute CINV phase. Delayed nausea and vomiting is less well defined and controlled, with as many as 50% of patients experiencing nausea and vomiting in the 3 to 5 day period following the first day of chemotherapy. Both acute and delayed CINV remain a significant problem in patients undergoing high-dose chemotherapy for autologous or allogeneic transplantation where up to 90% of patients experience CINV despite prophylactic strategies. Additional pharmacological interventions are clearly needed to optimize control of CINV. Neurokinin-1 receptor (NK-1) antagonists have been reported to improve the total control rates of acute CINV by approximately 25% compared to the standard combination of a 5-HT3 antagonists and dexamethasone alone. Cocquyt et al., reported that one dose of a NK-1 antagonist administered prior to cisplatin-based chemotherapy prevented delayed emesis in up to 72% of patients. Although promising, the role of these agents in CINV prevention and control is as yet undetermined. Acupuncture constitutes a nonpharmacological intervention for CINV. Chinese medicine holds that stimulating select points both on the body and the ear, that lie along meridians or life channels, can relieve diseases. From the previous studies, the P6 point, also known as the Neiguan point or G-Jo point no. 10, is located 2 cun (Chinese inch, equivalent to the width of an individual's thumb) proximal to the distal wrist crease, between the tendons of the palmaris longus and flexor carpi radialis. P6 acupuncture was shown to reduce the incidence and severity of nausea and vomiting in the postoperative setting, morning sickness, and the P6 transcutaneous electrical stimulation (TCES) therapy was shown to enhance the antiemetic action of ondansetron in patients receiving highly emetic chemotherapy treatment. Auricular acupuncture consisted of needle insertion in one ear at four points: (1) sympathetic - located in the terminal of the inferior antihelix crus; (2) stomach -located around the area where the helix crus terminates; (3) shinmoon - located at the bifurcating point between superior and inferior antihelix crus and the lateral 1/3 of the triangular fossa; and (4) occiput - located at the posterior superior corner of the lateral aspect of the antitragus have been reported to be effective in reducing PONV. The purpose of this study was to evaluate auricular acupuncture as an antiemetic treatment compared with sham acupuncture and with no acupuncture in patients receiving moderately-high to highly emetogenic chemotherapy.
The study is a three group, randomized, examiner-blind, crossover controlled trial. It is to evaluate the efficacy and safety of auricular acupuncture in patients receiving moderately-high to highly emetogenic chemotherapy from National Taiwan University Hospital. 120 eligible patients receiving moderately-high to highly emetogenic chemotherapy who fulfill the inclusion/exclusion criteria and complete the informed consent form will be recruited.
After the washout period of 2 weeks, the subjects will be required to take the medication for preventing acute CINV including combination therapy with a 5-HT3 antagonist and a corticosteroid for moderately-high to highly emetogenic chemotherapy. The patients will be divided into three groups (auricular acupuncture treatment group, sham auricular acupuncture treatment group, and non-treatment group) in order to test the effectiveness of auricular acupuncture. Group 1 patients will receive no treatment (control), after completion of the 1st chemotherapy course, Group 2 patients will receive auricular acupuncture treatment at the 2nd and 4th chemotherapy courses and will receive sham auricular acupuncture at the 3rd chemotherapy course, while Group 3 will receive sham auricular acupuncture at the 2nd and 4th chemotherapy courses and will receive auricular acupuncture at the 3rd chemotherapy course. At baseline visit and course 1, 2, 3, and 4 after chemotherapy, every subject will have efficacy evaluations by FILE, vomiting visual analog scare, WHOQOL-BREF questionnaire and Chinese Disposition Classification. Simultaneously, they will be monitored on their vital signs, complete blood counts, urinalysis, and biochemical indicators at baseline visit and the end of the trial. The collected data will then be analyzed by SAS 8.2 package.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Department of Oncology, National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed carcinoma
Patients must have normal organ and marrow function as defined below:
- ANC greater than or equal to 1500/mcL
- Platelets greater than or equal to 100,000/mcL
- AST (SGOT)/ALT (SGPT) less than 5 x institutional upper limit of normal
- Creatinine within normal institutional limits, OR
- Creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels less than 1.5mg/dl
- Patients should have the ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients with known CAD, CVA, epilepsy, hypotension, hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
The subjects in arms A and B will receive auricular acupuncture.
The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
|
Subjects will be randomized to one of these arms.
The subjects in arm A and B will receive auricular acupuncture.
Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
|
Sham Comparator: B
The subjects in arms A and B will receive auricular acupuncture.
The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
|
Subjects will be randomized to one of these arms.
The subjects in arm A and B will receive auricular acupuncture.
Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
|
No Intervention: C
No treatment received.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
At baseline visit and course 1, 2, 3, and 4 after chemotherapy, every subject will have been efficacy evaluated by FILE, vomiting visual analog scale, WHOQOL-Brief questionnaire and Chinese Disposition Classification.
Time Frame: subject
|
subject
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chih-Hsin Yang, PhD, Deparment of Oncology, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9561702041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Auricular acupuncture
-
University Medicine GreifswaldNaemi-Wilke-Stift Guben Hospital - Anesthesia ServicesCompleted
-
Taipei Medical UniversityCompletedSalivary Gland DiseasesTaiwan
-
Emory UniversityCompleted
-
University Medicine GreifswaldCompleted
-
University Medicine GreifswaldCompleted
-
Kessler FoundationCompleted
-
University Medicine GreifswaldCompleted
-
Duke UniversitySubstance Abuse and Mental Health Services Administration (SAMHSA); The Duke...CompletedMusculoskeletal PainUnited States
-
Mike O'Callaghan Military HospitalCompleted